Pathology: mRCC - L1 - PDL1 positive;
mRCC - L1 - PDL1 positive | |||||
IMmotion-150 (At - PDL1>1%), 2018 | IMmotion-151 (PDL1 >1%), 2019 | IMmotion-150 (AtB - PDL1>1%), 2018 | JAVELIN Renal 101( PDL1>1%), 2019 | ||
atezolizumab plus bevacizumab | 2 | T1 | T1 | ||
avelumab plus axitinib | 1 | T1 | |||
atezolizumab alone | 1 | T1 | |||
sunitinib | 0 | T0 | T0 | T0 | T0 |